Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body...